Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocetinostat plus Azacitidine in MDS
NCT02018926Phase 2Completed
- Sponsor
- Mirati Therapeutics
- Start
- Dec 2013
- Primary completion
- Sep 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mocetinostat in myelodysplastic syndrome (MDS), sponsored by Mirati Therapeutics. Started Dec 2013; status: completed.
02
Drugs
mocetinostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02018926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02018926.